Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells

Biomedicine and Pharmacotherapy

Volumn 81, Issue , 2016, Pages 31-37

  Kumar, Devbrat ^a   Basu, Soumya ^a   Parija, Lucy ^b   Rout, Deeptimayee ^a   Manna, Sanjeet ^a   Dandapat, Jagneshwar ^a   Debata, Priya Ranjan ^b  

^a UTKAL UNIVERSITY   (India)

^b Maharaja Sriram Chandra Bhanja Deo University   (India)

Author keywords

Apoptosis; Cervical cancer; Curcumin; Ellagic acid; HeLa cells; p53

Indexed keywords

CURCUMIN; ELLAGIC ACID; PROTEIN P53; REACTIVE OXYGEN METABOLITE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MESSENGER RNA; PROTEIN BAX; VIRAL PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; PRIORITY JOURNAL; DOSE RESPONSE; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN STABILITY; UTERINE CERVIX TUMOR;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CURCUMIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELLAGIC ACID; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; PROTEIN STABILITY; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS;

EID: 84962765465     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.03.037     Document Type: Article

References (35)

1. zurHausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 2000, 92(9):690-698.
2. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75(3):495-505.
3. Münger K., Scheffner M., Huibregtse J.M., Howley P.M. Interaction of HPV E6 and E7 oncoproteins with tumor suppressor gene products. Cancer Surv. 1992, 12:197-217.
4. Münger K., Phelps W.C. The human papillomavirus E7 protein as a transforming and transactivating factor. Biochim. Biophys. Acta 1993, 1155(1):111-123.
5. Chaturvedi A.K. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J. Adolesc. Health 2010, 46(Suppl. 4):20-26.
6. Pfaendler K.S., Tewari K.S. Changing paradigms in the systemic treatment of advanced cervical cancer. Am. J. Obstet. Gynecol. 2015, 9378(15):772-773.
7. Matsumura M., Takeshima N., Ota T., Omatsu K., Sakamoto K., Kawamata Y., Umayahara K., Tanaka H., Akiyama F., Takizawa K. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer-irinotecan and platinum chemotherapy. Gynecol. Oncol. 2010, 119(2):212-216.
8. McCormack M., Kadalayil L., Hackshaw A., Hall-Craggs M.A., Symonds R.P., Warwick V., Simonds H., Fernando I., Hammond M., James L., Feeney A., Ledermann J.A. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br. J. Cancer 2013, 108(12):2464-2469.
9. Raspagliesi F., Ditto A., Selvaggi L., Frigerio L., Melpignano M., Scambia G., Apolloni C., Scollo P., Pignata S., Panici P.B. A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer. Int. J. Gynecol. Cancer 2010, 20(9):1569-1575.
10. Moore D.H., Blessing J.A., Mc Quellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 2004, 22(15):3113-3119.
11. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61(2):69-90.
12. Matoda M., Tanigawa T., Omatsu K., Ushioda N., Yamamoto A., Okamoto S., Kawamata Y., Kato K., Umayahara K., Takeshima N. Platinum-free interval in second-line chemotherapy for recurrent cervical cancer. Int. J. Gynecol. Cancer 2013, 23(9):1670-1674.
13. Maher D.M., Bell M.C., O'Donnell E.A., Gupta B.K., Jaggi M., Chauhan S.C. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol. Carcinog. 2011, 50(1):47-57.
14. Debata P.R., Castellanos M.R., Fata J.E., Baggett S., Rajupet S., Szerszen A., Begum S., Mata A., Opitz L.M., Banerjee P. A novel curcumin-based vaginal cream vacurin selectively eliminates apposed human cervical cancer cells. Gynecol. Oncol. 2013, 129(1):145-153.
15. Lee W.H., Loo C.Y., Young P.M., Traini D., Mason R.S., Rohanizadeh R. Recent advances in Curcumin nanoformulation for cancer therapy. Expert Opin. Drug Deliv. 2014, 11(8):1183-1201.
16. Rocha A., Wang L., Penichet M., Martins-Green M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Res. Treat. 2012, 136(3):647-658.
17. Wang L., Ho J., Glackin C., Martins-Green M. Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl. Oncol. 2012, 5(5):344-355.
18. Radhika M., Ghoshal N., Chatterjee A. Comparison of effectiveness in antitumor activity between flavonoids and polyphenols of the methanolic extract of roots of Potentillafulgens in breast cancer cells. J. Complement. Integr. Med. 2012, 9(1):1553-3840.
19. Narayanan B.A., Geoffroy O., Willingham M.C., Re G.G., Nixon D.W. P53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in Ellagic acid treated cancer cells. Cancer Lett. 1999, 136(2):215-221.
20. Rajesh E., Sankari L.S., Malathi L., Krupaa J.R. Naturally occurring products in cancer therapy. J. Pharm. Bioallied Sci. 2015, 7(1):181-183.
21. Cragg G.M., Newman D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol. 2005, 100(1-2):72-79.
22. Yunos N.M., Beale P., Yu J.Q., Huq F. Synergism from sequenced combinations of Curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res. 2011, 31(4):1131-1140.
23. Singh M., Bhatnagar P., Srivastava A.K., Kumar P., Shukla Y., Gupta K.C. Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J. Biomed. Nanotechnol. 2011, 7(1):202.
24. Zeni O., Scarfì M.R. DNA damage by carbon nanotubes using the single cell gel electrophoresis technique. Methods Mol. Biol. 2010, 625:109-119.
25. Growdon W.B., Del Carmen M. Human papillomavirus-related gynecologic neoplasms: screening and prevention. Rev. Obstet. Gynecol. 2008, 1(4):154-161.
26. E, Lazcano-Ponce, Lörincz A.T., Salmerón J., Fernández A., Hernández I., Hernández-Avila M. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control 2010, 21(10):1693-1700.
27. Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Fresco L., Collingwood M., Williams C.J. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001, 358(9284):781-786.
28. Choi I.J., Cha M.S., Park E.S., et al. The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. J. Gynecol. Oncol. 2008, 19(2):129-134.
29. Hsu W.C., Chung N.N., Chen Y.C., Ting L.L., Wang P.M., et al. Comparison of surgery or radiotherapy on complications and quality of life in patients with the stage IB and IIA uterine cervical cancer. Gynecol. Oncol. 2009, 115(1):41-45.
30. Mondal S., Bandyopadhyay S., Ghosh M.K., Mukhopadhyay S., Roy S., Mandal C. Natural products: promising resources for cancer drug discovery. Anticancer Agents Med. Chem. 2012, 12(1):49-75.
31. Shukla S., Bharti A.C., Hussain S., Mahata S., Hedau S., Kailash U., Kashyap V., Bhambhani S., Roy M., Batra S., Talwar G.P., Das B.C. Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J. Cancer Res. Clin. Oncol. 2009, 135(12):1701-1709.
32. Oh P.S., Lim K.T. HeLa cells treated with phytoglycoprotein (150 kDa) were killed by activation of caspase 3 via inhibitory activities of NF-kappaB and AP-1. J. Biomed. Sci. 2007, 14(2):223-232.
33. Umesalma S., Nagendraprabhu P., Sudhandiran G. Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colonadenocarcinoma cells. Mol. Cell Biochem. 2015, 399(1-2):303-313.
34. Narayanan B.A., Geoffroy O., Willingham M.C., Re G.G., Nixon D.W. p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in Ellagic acid treated cancer cells. Cancer Lett. 1999, 136(2):215-221.
35. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., Steward W.P. Phase I clinical trial of oral Curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10(20):6847-6854.